Literature DB >> 22257968

The PMMA epidemic in Norway: comparison of fatal and non-fatal intoxications.

Merete Vevelstad1, Elisabeth Leere Øiestad, Gerrit Middelkoop, Inger Hasvold, Peer Lilleng, Gerd Jorunn M Delaveris, Tormod Eggen, Jørg Mørland, Marianne Arnestad.   

Abstract

During a 6 month period (July 2010-January 2011) we observed 12 fatal intoxications and 22 non-fatal cases related to the drug paramethoxymethamphetamine (PMMA) in Norway (4.8 mill inhabitants). This toxic designer drug, also known as "Death", is occasionally found in street drugs offered as "ecstasy" or "amphetamine". The present study aimed to evaluate the cause of death, and to compare the PMMA blood concentrations in fatal and non-fatal cases. Methods for identification and quantification of PMMA are presented. The median age of fatalities was 30 years (range 15-50) with 67% males; in non-fatal cases 27 years (20-47) with 86% males. In the 12 fatalities, the median PMMA blood concentration was 1.92 mg/L (range 0.17-3.30), which is in the reported lethal range of 0.6-3.1 mg/L in peripheral blood and 1.2-15.8 mg/L in heart blood. In the 22 non-fatal cases, the median PMMA concentration was 0.07 mg/L (range 0.01-0.65). Poly-drug use was frequent both in fatal and non-fatal cases. The PMA concentrations ranging from 0.00 to 0.26 mg/L in both groups likely represented a PMMA metabolite. Three fatalities were attributed to PMMA only, six to PMMA and other psychostimulant drugs, and three to PMMA and CNS depressant drugs, with median PMMA concentrations of 3.05 mg/L (range 1.58-3.30), 2.56 (1.52-3.23) and 0.52 mg/L (0.17-1.24), respectively. Eight victims were found dead, while death was witnessed in four cases, with symptoms of acute respiratory distress, hyperthermia, cardiac arrest, convulsions, sudden collapse and/or multiple organ failure. In summary, all fatalities attributed to PMMA had high PMMA blood concentrations compared to non-fatal cases. Our sample size was too small to evaluate a possible impact of poly-drug use. A public warning is warranted against use and overdose with illegal "ecstasy" or "speed" drugs.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22257968     DOI: 10.1016/j.forsciint.2011.12.014

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  6 in total

1.  Deaths from exposure to paramethoxymethamphetamine in Alberta and British Columbia, Canada: a case series.

Authors:  Jennifer J E Nicol; Mark C Yarema; Graham R Jones; Walter Martz; Roy A Purssell; Judy C MacDonald; Ian Wishart; Monica Durigon; Despina Tzemis; Jane A Buxton
Journal:  CMAJ Open       Date:  2015-01-13

2.  Fatalities associated with NPS stimulants in the Greater Cologne area.

Authors:  Sabrina Lehmann; Tobias Kieliba; Mario Thevis; Markus A Rothschild; Katja Mercer-Chalmers-Bender
Journal:  Int J Legal Med       Date:  2019-11-18       Impact factor: 2.686

3.  Investigation of Biotransformation Products of p-Methoxymethylamphetamine and Dihydromephedrone in Wastewater by High-Resolution Mass Spectrometry.

Authors:  Juliet Kinyua; Aikaterini K Psoma; Nikolaos I Rousis; Maria-Christina Nika; Adrian Covaci; Alexander L N van Nuijs; Νikolaos S Τhomaidis
Journal:  Metabolites       Date:  2021-01-25

4.  The influence of viewing a headline about ecstasy/Molly adulteration on future intentions to use.

Authors:  Joseph J Palamar; Patricia Acosta; Charles M Cleland
Journal:  J Subst Use       Date:  2019-09-12

5.  Patients presenting with acute poisoning to an outpatient emergency clinic: a one-year observational study in Oslo, Norway.

Authors:  Odd Martin Vallersnes; Dag Jacobsen; Øivind Ekeberg; Mette Brekke
Journal:  BMC Emerg Med       Date:  2015-08-13

6.  Presentations due to acute toxicity of psychoactive substances in an urban emergency department in Switzerland: a case series.

Authors:  Evangelia Liakoni; Patrick C Dolder; Katharina M Rentsch; Matthias E Liechti
Journal:  BMC Pharmacol Toxicol       Date:  2016-05-26       Impact factor: 2.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.